Cabozantinib (Cabometyx,Cabodx)

Cabozantinib is an oral multi-targeted tyrosine kinase inhibitor with broad-spectrum anticancer activity.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Cabozantinib Drug News

FDA Approves Cabozantinib (Cabometyx) for Previously Treated Patients with Advanced Neuroendocrine T

On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【More】
Update: 05 Mar,2026Source: BigbearViews: 89
The FDA has approved cabozantinib (Cabometyx) for patients with previously treated advanced neuroend

On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【More】
Update: 28 Feb,2026Source: BigbearViews: 86

Bigbear Pharmaceutical